相关实验视频
Updated: Jan 8, 2026

08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
4.7K
Hv1抑制通过恢复微质线粒体功能和增强线粒体转移来拯救AD病理
Jiayuan Lin1, Huayun Han2, Kexin Wu1
1Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Experimental & molecular medicine
|December 16, 2025
概括
电压通道1 (Hv1) 驱动在阿尔茨海默病 (AD) 中的微线粒体功能障碍. 用YHV98-4抑制Hv1恢复了线粒体功能,增强了清除,并改善了认知结果.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 线粒体生物学 线粒体生物学
背景情况:
- 阿尔茨海默氏病 (AD) 的特点是病理和神经炎症,其中微质细胞起着关键作用.
- 微质线粒体的健康对于免疫恒温和清除AD病理性tau至关重要.
- 在阿尔茨海默病中微质线粒体功能障碍的机制尚不清楚,这阻碍了治疗策略.
研究的目的:
- 调查电压通道1 (Hv1) 在阿尔茨海默病中微线粒体功能障碍中的作用.
- 探索在AD中准HV1的治疗潜力.
主要方法:
- 利用AD小鼠模型检查激活的微质中的Hv1表达.
- 评估线粒体功能,包括电子运输链活动,氧化应激,ATP生产和线粒体衰变.
- 评估了HV1特异性抑制剂YHV98-4对微质功能,清除和认知表现的影响.
主要成果:
- 在AD小鼠模型中,Hv1在激活的微质中被上调.
- 由YHV98-4抑制Hv1逆转了线粒体功能障碍,包括氧化应激和受损的ATP产生.
- YHV98-4治疗改善了tau清除和增强了微细胞到神经元的线粒体转移,挽救了神经元损伤并改善了认知.
结论:
- 在阿尔茨海默病中,Hv1在调解微质线粒体功能障碍方面发挥着至关重要的作用.
- 用YHV98-4向Hv1代表了阿尔茨海默病的有希望的治疗策略,通过恢复线粒体功能和增强神经保护机制.
更多相关视频
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.1K
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.1K
相关概念视频
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K